<DOC>
	<DOC>NCT00451490</DOC>
	<brief_summary>Phase advance of HRV will be anticipated in agomelatine group. It is anticipated that both agomelatine and floxentine will increase HRV at the end of the treatment.</brief_summary>
	<brief_title>The Effect of Agomelatine or Fluoxentine on Heart Rate Variability in Patients With Major Depressive Disorder</brief_title>
	<detailed_description>Phase advance of HRV will be anticipated in agomelatine group. It is anticipated that both agomelatine and floxentine will have equal efficacy in improvement of depressive symptoms and increasement of HRV at the end of the treatment.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>S 20098</mesh_term>
	<criteria>Asian patients Male or female 18 to 65 years outpatients DSMIVTR criteria for Major Depressive Disorder Patients with cardiac conditions and other physical conditions contraindicated for drug study Shift worker Patients known to be nonresponders to fluoxetine treatment Pregnancy, or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>agomelatin</keyword>
	<keyword>prozac</keyword>
	<keyword>heart rate variability</keyword>
	<keyword>major depression</keyword>
	<keyword>sleep</keyword>
	<keyword>depressive symptoms</keyword>
</DOC>